PYPD
PolyPid Ltd.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
PolyPid Ltd.
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
PolyPid Ltd.
5.35
−0.11 · −2.01%
post 5.72 +6.87%
No changes.
No changes.
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; no measured co-movers for PolyPid Ltd..
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; no measured co-movers for PolyPid Ltd..
Annual filing, covered
20-F parsed · Feb 25 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Feb 25 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
News
Expected move
No implied move.
| Manager | Value | % base | |
|---|---|---|---|
| AIGH | $7.6M | 45.60% | −5.58% |
| Rosalind | $2.0M | 11.80% | −34.87% |
| DAFNA | $1.1M | 6.30% | 0.00% |
| Morgan Stanley | $625,531 | 3.73% | −30.39% |
| Renaissance Technologies | $592,425 | 3.53% | +527.12% |
| Manager | Value | % base | |
|---|---|---|---|
| AIGH | $7.6M | 45.60% | −5.58% |
| Rosalind | $2.0M | 11.80% | −34.87% |
| DAFNA | $1.1M | 6.30% | 0.00% |
| Morgan Stanley | $625,531 | 3.73% | −30.39% |
| Renaissance Technologies | $592,425 | 3.53% | +527.12% |